<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03037541</url>
  </required_header>
  <id_info>
    <org_study_id>Carac &amp; Cryo</org_study_id>
    <nct_id>NCT03037541</nct_id>
  </id_info>
  <brief_title>Cryosurgery and Cream Combination for Actinic Keratosis</brief_title>
  <official_title>A Single-Center, Randomized, Single-Blinded, Placebo-Controlled Trial on the Efficacy of Cryosurgery and 5-Fluorouracil 0.5% Cream Combination Therapy for the Treatment of Actinic Keratosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wake Forest University Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wake Forest University Health Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Carac 0.5% cream is approved for daily topical treatment of AK's for up to four weeks as
      tolerated, though local irritation often occurs within the first week of treatment and
      increases in a dose-dependent manner. In this study, the investigators will examine the
      combination of standard cryosurgery treatment followed by a shortened course of topical
      fluorouracil cram. The investigators anticipate that a one week treatment course will
      maintain overall effectiveness when combined with previous cryosurgery, but will reduce the
      overall adverse effects of topical therapy due to the reduced treatment time and the presence
      of fewer baseline lesions to treat. This treatment approach may provide a more acceptable
      risk/benefit ratio option for patients with more extensive disease and simplify standard
      combination treatment options. The primary objective is to evaluate the efficacy of
      combination cryosurgery and 5-fluorouracil0.5% cream, compared to combination cryosurgery and
      placebo in the treatment of actinic keratosis lesions. The efficacy of this combination
      therapy will be evaluated by assessing AK lesion clearance. The primary efficacy parameter
      will be 10% clearance of all AK lesions from treatment initiation to end-of-treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized (1:1), single-blind, placebo controlled, single center prospective
      study. Subjects will first undergo cryosurgery of all clinically apparent AK lesions, limited
      to the face or balding scalp. Three weeks after cryosurgery, subjects will then be randomized
      (1:1 according to standard randomization tables) and directed to apply either Carac 0.5%
      cream or placebo cream (Cetaphil Cream) to the face or balding scalp at bedtime for seven
      consecutive days, washed off each following morning. Each does of study cream will be applied
      at approximately the same time of day and will remain on the skin for approximately eight
      hours. Subject evaluation, Investigator Global Assessments, Quality of Life lesion counts and
      photography shall be performed at Baseline. At Week 3, study drug will be dispensed and the
      global assessments and assessment of improvement will be performed. A Medication Tolerability
      Assessment will occur at Week 4 when the study drug will be returned. Investigator Global
      Assessment, lesion count, Global Assessment of Improvement and Quality of Life will be
      measured at Week 8 and Week 26 (or end of study). Photography will be done at Week 26 or end
      of study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 5, 2011</start_date>
  <completion_date type="Actual">October 29, 2013</completion_date>
  <primary_completion_date type="Actual">October 29, 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number Participants With 100% Clearance</measure>
    <time_frame>24 weeks</time_frame>
    <description>The primary endpoint is number of participants that receive 100% clearance of AK lesions from treatment initiation to end of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With 75% Clearance</measure>
    <time_frame>24 weeks</time_frame>
    <description>The secondary endpoint is number of participants that receive 75 % clearance of</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Actinic Keratosis</condition>
  <arm_group>
    <arm_group_label>Group 1 Carac (fluorouracil) 0.5% cream</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Carac cream (fluorouracil) 0.5% applied daily on the face for one week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Cetaphil cream applied daily on the face for one week</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carac Cream</intervention_name>
    <description>Carac Cream will be used once daily for seven consecutive days</description>
    <arm_group_label>Group 1 Carac (fluorouracil) 0.5% cream</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Cetaphil cream</intervention_name>
    <description>Placebo Cetaphil Cream will be used once daily for seven consecutive days</description>
    <arm_group_label>Group 2 Placebo</arm_group_label>
    <other_name>Cetaphil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must be male or female and at least 18 years of age. Each subject must demonstrate
             good health as determined by a baseline medical history.

          -  Female subjects myst be of either non-childbearing potential, or childbearing
             potential provided: negative urine pregnancy test and using two acceptable methods of
             effective contraception (abstinence, birth control pills.patch, DepoProvera, tubal
             ligation, vasectomy of the partner in a monogamous relationship, condoms and
             spermicidal form or gel and/or cervical cap or sponge), as determined by the
             investigator

          -  At least eight clinically typical, visible and discrete AK lesions within the
             treatment area on the face or balding scalp

          -  Subjects must be able and willing to comply with study procedures and have provided
             written informed consent.

        Exclusion Criteria:

          -  Cosmetic or therapeutic procedures (e.g., use of liquid nitrogen, surgical excision,
             curettage, dermabrasion, medium or greater depth chemical peel, laser resurfacing)
             within the selected treatment area in the previous four weeks.

          -  Treatment with systemic medications that suppress the immune system within the
             previous four weeks.

          -  Field treatments with topical 5-FU, imiquimod, diclofenac, or photodynamic therapy, or
             more widespread field treatment with dermabrasion, medium or greater depth chemical
             peel, or laser resurfacing within the previous six months.

          -  Any known dihydropyrimidine dehydrogenase enzyme deficiency.

          -  In addition, subjects who have any skin condition or disease that may require
             concurrent therapy or may confound the evaluation as determined by the investigator,
             or a history of hypersensitivity to any of the formulation components will be excluded
             from study.

          -  Subjects may not use other topical agents such as glycolic acid products,
             alpha-hydroxy acid products, retinoids and chemical peel agents on teh treatment area
             while on study. The use of these products are not allowed four weeks prior to study
             enrollment. Introduction of any other prescription medication, topical or systemic for
             actinic keratosis while participating in the study is not permitted.

          -  Pregnant women, women who are breast feeding, or women of childbearing potential who
             are not practicing two acceptable methods of effective contraception.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph Jorizzo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wake Forest University Health Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wake Forest University Health Sciences Department of Dermatology</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2011</study_first_submitted>
  <study_first_submitted_qc>January 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 31, 2017</study_first_posted>
  <results_first_submitted>January 31, 2017</results_first_submitted>
  <results_first_submitted_qc>January 31, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 23, 2017</results_first_posted>
  <last_update_submitted>November 1, 2017</last_update_submitted>
  <last_update_submitted_qc>November 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Wake Forest</keyword>
  <keyword>Actinic Keratosis</keyword>
  <keyword>Cryosurgery</keyword>
  <keyword>Cream</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratosis</mesh_term>
    <mesh_term>Keratosis, Actinic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Group 1 Carac (Fluorouracil) 0.5% Cream</title>
          <description>Carac cream (fluorouracil) 0.5% applied daily on the face for one week
Carac Cream: Carac Cream will be used once daily for seven consecutive days</description>
        </group>
        <group group_id="P2">
          <title>Group 2 Placebo</title>
          <description>Placebo Cetaphil cream applied daily on the face for one week
Placebo Cetaphil cream: Placebo Cetaphil Cream will be used once daily for seven consecutive days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group 1 Carac (Fluorouracil) 0.5% Cream</title>
          <description>Carac cream (fluorouracil) 0.5% applied daily on the face for one week
Carac Cream: Carac Cream will be used once daily for seven consecutive days</description>
        </group>
        <group group_id="B2">
          <title>Group 2 Placebo</title>
          <description>Placebo Cetaphil cream applied daily on the face for one week
Placebo Cetaphil cream: Placebo Cetaphil Cream will be used once daily for seven consecutive days</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
            <count group_id="B2" value="30"/>
            <count group_id="B3" value="60"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="59"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number Participants With 100% Clearance</title>
        <description>The primary endpoint is number of participants that receive 100% clearance of AK lesions from treatment initiation to end of treatment</description>
        <time_frame>24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1 Carac (Fluorouracil) 0.5% Cream</title>
            <description>Carac cream (fluorouracil) 0.5% applied daily on the face for one week
Carac Cream: Carac Cream will be used once daily for seven consecutive days</description>
          </group>
          <group group_id="O2">
            <title>Group 2 Placebo</title>
            <description>Placebo Cetaphil cream applied daily on the face for one week
Placebo Cetaphil cream: Placebo Cetaphil Cream will be used once daily for seven consecutive days</description>
          </group>
        </group_list>
        <measure>
          <title>Number Participants With 100% Clearance</title>
          <description>The primary endpoint is number of participants that receive 100% clearance of AK lesions from treatment initiation to end of treatment</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With 75% Clearance</title>
        <description>The secondary endpoint is number of participants that receive 75 % clearance of</description>
        <time_frame>24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1 Carac (Fluorouracil) 0.5% Cream</title>
            <description>Carac cream (fluorouracil) 0.5% applied daily on the face for one week
Carac Cream: Carac Cream will be used once daily for seven consecutive days</description>
          </group>
          <group group_id="O2">
            <title>Group 2 Placebo</title>
            <description>Placebo Cetaphil cream applied daily on the face for one week
Placebo Cetaphil cream: Placebo Cetaphil Cream will be used once daily for seven consecutive days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With 75% Clearance</title>
          <description>The secondary endpoint is number of participants that receive 75 % clearance of</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Group 1 Carac (Fluorouracil) 0.5% Cream</title>
          <description>Carac cream (fluorouracil) 0.5% applied daily on the face for one week
Carac Cream: Carac Cream will be used once daily for seven consecutive days</description>
        </group>
        <group group_id="E2">
          <title>Group 2 Placebo</title>
          <description>Placebo Cetaphil cream applied daily on the face for one week
Placebo Cetaphil cream: Placebo Cetaphil Cream will be used once daily for seven consecutive days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>viral infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>tooth pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>joint pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>basal cell carcinoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Joseph Jorizzo, MD</name_or_title>
      <organization>Wake Forest University Health Sciences</organization>
      <phone>336-716-3775</phone>
      <email>jjorizzo@wakehealth.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

